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     The exact etiopathogenesis of SLE is still unknown and there is no 
gold standard of treatment for the autoimmune disease. Female 
patients diagnosed with SLE should be counseled on the risks of 
pregnancy as the majority of SLE patients are women of child-
bearing age. Since powerful immunosuppressants and cytotoxic 
drugs are used for treatment of SLE, pregnancy presents a unique 
challenge for medical management. Although pregnancy places the 
patient at higher risk for complications, most patients can have 
successful pregnancies. Providers must have a good understanding 
of the disease and provide patients with appropriate education and 
support to enable SLE patients to maintain wellbeing and lead active 
lives (Ferenkeh-Koroma, 2012).  
     There are 20-150 cases of SLE reported 
per 100,000 people with the highest 
prevalence in Brazil (Tsokos, 2011). In the 
U.S., people of African, Hispanic and Asian 
ancestry have a higher incidence than 
those of European ancestry (Tsokos, 2011). 
Multidisciplinary management of the 
pregnant SLE patient has improved disease 
management and pregnancy outcomes 
dramatically over the last 20 years (Ateka-
Barrutia & Khamashta, 2013). 
     Many antibodies are present and 
measured in patients with SLE. 
Autoantibodies including antinuclear 
antibody (ANA), anti-double stranded (ds) 
DNA and anti-Smith have been found in 
88% of SLE patients up to 9.4 years before 
the patient is ever diagnosed with SLE 
(Marks & Tullus, 2011). Anti-dsDNA 
antibodies are particularly important 
because they have a high specificity for 
disease activity (Marks & Tullus, 2011). 
Antiphospholipid antibodies are present in 
30-40% of women with SLE (Tower, 
Mathen, Crocker, & Bruce, 2013). The 
presence of these antibodies places the 
pregnant SLE patient at greater risk for 
poor outcomes with approximately one 
third developing thrombotic events and 
miscarriages (Ferenkeh-Koroma, 2012). 
Low dose aspirin or low molecular-weight 
heparin can significantly decrease 
complications resulting from 
antiphospholipid antibodies and increase 
the live birth rate by sevenfold (Ferenkeh-
Koroma, 2012).  
Conclusion 
 
Significance of Pathology 
     SLE can also have an effect on the growing 
fetus in the form of neonatal lupus (NL). NL is 
mediated by maternal anti-Ro/SSA and anti-
La/SSB antibodies which can cross the 
placenta affecting the fetus (Nalli et al., 
2013). Only 1% of infants will develop NL with 
the majority having cutaneous lesions that 
are photosensitive to direct sunlight 
(Johnson, 2014). However, congenital  heart 
block (CHB) is the most severe form of NL 
with a 10-20% perinatal death rate and most 
surviving children in need of a permanent 
pacemaker (Ateka-Barrutia & Khamashta, 
2013).  
     Treatments typically include topical 
applications for skin rash, NSAIDS, 
corticosteroids, immunosuppressants, and 
antimalarial drugs (Ferenkeh-Koroma, 2012). 
Management is based on symptoms and the 
degree of organ involvement and the 
treatment regimen may change relative to 
flares and remissions (Ferenkeh-Koroma, 
2012).  
    Systemic lupus erythematosus 
(SLE) is a life-long, life-threatening 
autoimmune disease which can 
affect any organ in the body 
(Marks & Tullus, 2011). SLE 
disproportionately affects women 
in a ratio of 9:1 compared to men 
with most women being affected 
during child-bearing age (15-50 
years) (Ferenkeh-Koroma, 2012). 
Pregnancy represents a challenge 
for the patient with SLE.  Pregnant 
patients with SLE are considered 
high-risk for multiple medical and 
obstetric complications, as flares 
are related to increased 
irreversible organ damage (Ateka-
Barrutia & Khamashta, 2013). 
Severe flares are also associated 
with poor fetal outcomes (Peart & 
Clowse, 2014). Successful 
pregnancies happen in 67% of 
women with lupus compared to 
85% in the general population 
(Ferenkeh-Koroma, 2012). There 
is a 20-fold risk in maternal 
mortality and an increased rate of 
hypertension, pre-gestational 
diabetes, renal impairment, 
pulmonary hypertension, major 
infections, thrombotic events, and 
other hematological complications 
in patients with lupus (Ateka-
Barrutia & Khamashta, 2013). 
There is a higher risk for preterm 
labor in patients with lupus with 
25% of pregnancies resulting in 
delivery before 37 weeks 
gestation (Ferenkeh-Koroma, 
2012). There is also a greater risk 
for pre-eclampsia, intrauterine 
growth restriction (IUGR) and 
cesarean section (Ateka-Barrutia 
& Khamashta, 2013).  
     In SLE, the body produces auto-
antibodies which attack healthy cells, 
tissues and organs (Ferenkeh-
Koroma, 2012). “Common symptoms 
of lupus include extreme fatigue, 
kidney problems, painful or swollen 
joints and skin rashes” (Ferenkeh-
Koroma, 2012, p. 49).  A combination 
of genetic, environmental, 
immunoregulatory, hormonal, and 
epigenetic factors play a role in the 
predisposition and development of 
SLE (Tsokos, 2011). As with most 
autoimmune diseases, SLE is 
characterized by disease flares 
followed by periods of remission 
(Nalli et al., 2014).  
     SLE is caused by a complex 
assortment of immune abnormalities. 
Overactive B cells, abnormally 
activated T cells and antigen-
presenting cells results in the 
productions of inflammatory 
cytokines, apoptotic cells, diverse 
autoantibodies and immune 
complexes (Marks & Tullus, 2011). 
Deposits of immune complexes are 
the main cause of organ injury in SLE.  
Immune complexes are formed in 
large amounts as antinuclear 
antibodies and bind to nuclear 
material in blood and tissues, but 
cannot be cleared easily because the 
Fc and complement receptors are 
deficient (Tsokos, 2011). The immune 
complexes can bind to tissue specific 
cells which triggers the complement 
cascade and other mediators of 
inflammation (Tsokos, 2011).  
     During pregnancy, the health of the 
fetus is dependent upon the health of the 
mother. An unhealthy mother can inhibit 
her ability to carry a pregnancy to full-
term. Uterine-placental insufficiency 
caused by poor vascularization 
contributes to multiple pregnancy 
complications (Ostensen & Clowse, 2013). 
Endothelial dysfunction and cell damage 
leading to poor placental blood flow is 
the main cause of IUGR and possibly early 
preeclampsia (Ostensen & Clowse, 2013). 
Preterm labor may be triggered by 
several different routes in the SLE 
patient. The most significant predictor of 
preterm birth is lupus activity during the 
course of the pregnancy (Ostensen & 
Clowse, 2013). Inflammation from 
infection, oral prednisone, and elevated 
anti-dsDNA and hypocomplementemia 
are also associated with preterm birth 
(Ostensen & Clowse, 2013). Other 
antibodies, such as antiphospholipid 
antibodies, are associated with venous 
and arterial thrombosis and miscarriage, 
fetal death and preterm births (Stanhope, 
White, Moder, Smyth, & Garovic, 2012). 
Nursing Considerations 
     Due to the various and vast effects SLE can have on the body, 
pregnancy represents an incredible challenge for healthcare providers. 
Preconception counseling is recommended for women with SLE hoping 
to become pregnant. It is encouraged for the woman to not get 
pregnant until the disease has been in remission for at least 6 months 
as this is associated with better outcomes for the mother and infant 
(Nalli et al., 2013). A multidisciplinary approach including an 
obstetrician experienced in high risk pregnancies in collaboration with 
a rheumatologist familiar with SLE should be utilized for the 
management of the patient (Ferenkeh-Koroma, 2012). Screenings for 
antibodies such as the ANA, anti-Ro/La, anti-dsDNA, and ASA should 
be done during the initial evaluation of the pregnant SLE patient. Anti-
dsDNA and hypocomplementemia also have been proven to be very 
helpful in determining pregnancy risks in a clinically active SLE 
(Clowse, Magder, & Petri, 2011). Most lupus flares during pregnancy 
occur during the first trimester and up to 30% may have flares 
between 2-8 weeks postpartum (Ferenkeh-Koroma, 2012). Treatment 
for SLE during pregnancy is critical and varies on a case by case basis. 
Multiple medications may be used, although some are contraindicated 
during pregnancy. Poor control of the disease during pregnancy may 
have damaging effects on the outcome for the mother and infant 
(Nalli, et al., 2013).  It is encouraging, though, that most women who 
become pregnant during remission can expect a normal pregnancy 
without any major complications (Ferenkeh- Koroma, 2012). Close 
monitoring and management of the pregnant SLE patient is imperative 
to ensure the best possible outcome for the mother and infant.  
Ateka-Barrutia, O., & Khamashta, M. A. (2013). The    
challenge of pregnancy for patients with SLE. Lupus, 
22(12), 1295-1308. doi:10.1177/0961203313504637 
 
Clowse, M. B., Magder, L. S., & Petri, M. (2011). The 
clinical utility of measuring complement and anti-
dsDNA antibodies during pregnancy in patients with 
systemic lupus erythematosus. Journal of 
Rheumatology, 38(6), 1012-
1016.doi:10.3899/jrheum.100746 
 
Ferenkeh-Koroma, A. (2012). Systemic lupus 
erythematosus: nurse and patient education. Nursing 
Standard, 26(39), 49-57. 
 
Johnson, B. (2014). Overview of neonatal lupus. 
Journal of Pediatric Healthcare, 28(4), 331-341. 
doi:10.1016/j.pedhc.2013.07.015 
 
Marks, S., & Tullus, K. (2012). Autoantibodies in 
systemic lupus erythematosus. Pediatric Nephrology, 
27(10), 1855-1868. doi:10.1007/s00467-011-2078-4 
 
Nalli, C., Iodice, A., Andreoli, L., Lojacono, A., Motta, 
M., Fazzi, E., & Tincani, A. (2014). The effects of lupus 
and antiphospholipid antibody syndrome on foetal 
outcomes. Lupus, 23(6), 507-517. 
doi:10.1177/0961203313501402 
 
Ostensen, M., & Clowse, M. (2013). Pathogenesis of 
pregnancy complications in systemic lupus 
erythematosus. Current Opinion in Rheumatology, 
25(5), 591-596. doi:10.1097/BOR.0b013e328363ebf7 
 
Peart, E., & Clowse, M. B. (2014). Systemic lupus 
erythematosus and pregnancy outcomes: an update 
and review of the literature. Current Opinion in 
Rheumatology, 26(2), 118-123. 
doi:10.1097/BOR.0000000000000030 
 
Stanhope, T., White, W., Moder, K., Smyth, A., & 
Garovic, V. (2012). Obstetric nephrology: lupus and 
lupus nephritis in pregnancy. Clinical Journal of the 
American Society of Nephrology, 7(12), 2089-2099. 
doi:10.2215/CJN.12441211 
 
Tower, C., Mathen, S., Crocker, I., & Bruce, I. N. 
(2013). Regulatory T cells in systemic lupus 
erythematosus and pregnancy. American Journal of 
Reproductive Immunology (New York, N.Y.: 1989), 
69(6), 588-595. doi:10.1111/aji.12081 
 
Tsokos, G. (2011). Systemic lupus erythematosus. New 
England Journal of Medicine, 365(22), 2110-2121. 
 Pathogenesis of SLE 
(Tsokos, 2011, p. 2112) 
Decreased blood flow through 
placental spiral arteries in SLE 
Copyright 2013 by Lippincott 
Williams & Wilkins Common butterfly rash in SLE 
Copyright 2010 by Dermnet.com  
